[Series] The changing therapeutic landscape of small-cell lung cancer

A Lancet Series review synthesises the past decade of advances in small-cell lung cancer (SCLC) biology and the novel therapeutic strategies they are enabling. SCLC remains an exceptionally aggressive, highly proliferative malignancy that is frequently metastatic at diagnosis and rapidly becomes refractory to standard chemotherapy despite high initial response rates. The article maps how improved understanding of tumour heterogeneity and molecular subtypes is now translating into multiple new preclinical and clinical treatment approaches.